Malignant Primary Gliomas

Oncology
2
Pipeline Programs
2
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
2
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Kazia Therapeutics
Kazia TherapeuticsAustralia - Sydney
1 program
1
PaxalisibPhase 1/2Small Molecule
United Therapeutics
United TherapeuticsMD - Silver Spring
1 program
1
PaxalisibPhase 1/2Small Molecule1 trial
Active Trials
NCT07391215Recruiting64Est. Jun 2029

Trial Timeline

Clinical trial activity over time

2026
2027
2028
2029
United TherapeuticsPaxalisib

Clinical Trials (1)

Total enrollment: 64 patients across 1 trials

5G-PEARL: Paxalisib in Malignant Brain Tumours

Start: Jan 2026Est. completion: Jun 202964 patients
Phase 1/2Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 64 patients
2 companies competing in this space